Skip to main content
Top
Published in: Annals of Hematology 7/2006

01-07-2006 | Original Article

Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma

Authors: Masanori Umeda, Shinya Okuda, Haruka Izumi, Daisuke Nagase, Yoshinori Fujimoto, Yasuyuki Sugasawa, Chiaki Arai, Kazuhiko Natori, Masako Katoh, Yasunobu Kuraishi

Published in: Annals of Hematology | Issue 7/2006

Login to get access

Abstract

We studied the serum phosphorus (P) level of 110 patients with multiple myeloma (MM) (age range 42–83 years, median 62 years) and evaluated the relationship between that and other prognostic factors. Serum P level significantly correlated with the prognostic factors that are relevant to renal dysfunction: serum creatinine (P<0.00000001), serum β2-microglobulin (P=0.00000088), serum uric acid (P=0.0000014), and corrected serum calcium (cCa P=0.000067). Although it also correlated with the percentage of plasma cells in bone marrow nucleated cells (BMPC%) and the hemoglobin (Hb) and leukocyte counts, the significance was less than for the other four prognostic factors. Serum creatinine, BMPC%, leukocyte count, serum uric acid, bone lesions, β2-microglobulin, and serum cCa were all significantly higher and Hb significantly was lower in the MM patients with hyperphosphatemia (serum P>3.8 mg/dl). The survival time was significantly shorter in these patients (P=0.000087). Multivariate analysis (Cox’s proportional hazards regression model) showed that the serum P level is a significant negative prognostic factor in MM patients.
Literature
1.
go back to reference Holick MF, Krane SM, Potts JT (1987) Phosphorus, disorders of bone and mineral metabolism. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS (eds) Harrison’s principles of internal medicine, 11th edn. McGraw-Hill, New York, pp 1859–1860 Holick MF, Krane SM, Potts JT (1987) Phosphorus, disorders of bone and mineral metabolism. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS (eds) Harrison’s principles of internal medicine, 11th edn. McGraw-Hill, New York, pp 1859–1860
2.
go back to reference Pettersson T, Hortling L, Teppo AM, Toetterman KJ, Fyhrquist F (1987) Phosphate binding by a myeloma protein. Acta Med Scand 222:89–91PubMed Pettersson T, Hortling L, Teppo AM, Toetterman KJ, Fyhrquist F (1987) Phosphate binding by a myeloma protein. Acta Med Scand 222:89–91PubMed
3.
go back to reference Mandry JM, Posner MR, Tucci JR, Eil C (1991) Hyperphosphatemia in multiple myeloma due to a phosphate-binding immunoglobulin. Cancer 68:1092–1094PubMedCrossRef Mandry JM, Posner MR, Tucci JR, Eil C (1991) Hyperphosphatemia in multiple myeloma due to a phosphate-binding immunoglobulin. Cancer 68:1092–1094PubMedCrossRef
4.
go back to reference Busse JC, Gelhard MA, Byrenes JJ, Hellman R, Vaamonde CA (1987) Pseudohyperphosphatemia and dysproteinemia. Arch Intern Med 147:2045–2046PubMedCrossRef Busse JC, Gelhard MA, Byrenes JJ, Hellman R, Vaamonde CA (1987) Pseudohyperphosphatemia and dysproteinemia. Arch Intern Med 147:2045–2046PubMedCrossRef
5.
go back to reference Sonnenblick M, Eylath U, Brisk R, Eldad C, Hershko C (1986) Paraprotein interference with colorimetry of phosphate in serum of some patients with multiple myeloma. Clin Chem 32:1537–1539PubMed Sonnenblick M, Eylath U, Brisk R, Eldad C, Hershko C (1986) Paraprotein interference with colorimetry of phosphate in serum of some patients with multiple myeloma. Clin Chem 32:1537–1539PubMed
6.
go back to reference Adler SG, Laidlaw SA, Lubran MM, Kopple JD (1988) Hyperglobulinemia may spuriously elevate measured serum inorganic phosphate levels. Am J Kidney Dis 11:260–263PubMed Adler SG, Laidlaw SA, Lubran MM, Kopple JD (1988) Hyperglobulinemia may spuriously elevate measured serum inorganic phosphate levels. Am J Kidney Dis 11:260–263PubMed
7.
go back to reference Oren S, Feldman A, Turkot S, Lugassy G (1994) Hyperphosphatemia in multiple myeloma. Ann Hematol 69:41–43PubMedCrossRef Oren S, Feldman A, Turkot S, Lugassy G (1994) Hyperphosphatemia in multiple myeloma. Ann Hematol 69:41–43PubMedCrossRef
8.
go back to reference Marcu CB, Hotchkiss M (2004) Pseudohyperphosphatemia in a patient with multiple myeloma. Conn Med 68:71–77PubMed Marcu CB, Hotchkiss M (2004) Pseudohyperphosphatemia in a patient with multiple myeloma. Conn Med 68:71–77PubMed
9.
go back to reference Chronic Leukemia–Myeloma Taskforce, National Cancer Institute (1973) Proposed guidelines for protocol studies 11. Plasma cell myeloma. Cancer Chemother Rep 3 4:145–158 Chronic Leukemia–Myeloma Taskforce, National Cancer Institute (1973) Proposed guidelines for protocol studies 11. Plasma cell myeloma. Cancer Chemother Rep 3 4:145–158
10.
11.
go back to reference Alexanian R, Salmon S, Bonnet J, Gehan E, Haut A, Weick J (1977) Combination therapy for multiple myeloma. Cancer 40:2765–2771PubMedCrossRef Alexanian R, Salmon S, Bonnet J, Gehan E, Haut A, Weick J (1977) Combination therapy for multiple myeloma. Cancer 40:2765–2771PubMedCrossRef
12.
go back to reference Peto, R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient II: analysis and examples. Br J Cancer 35:l–39 Peto, R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient II: analysis and examples. Br J Cancer 35:l–39
13.
go back to reference Payne RB, Little AJ, Williams RB, Milner JR (1973) Interpretation of serum calcium in patients with abnormal proteins. BMJ 4:643–646PubMedCrossRef Payne RB, Little AJ, Williams RB, Milner JR (1973) Interpretation of serum calcium in patients with abnormal proteins. BMJ 4:643–646PubMedCrossRef
14.
go back to reference Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef
15.
go back to reference Cox DR (1972) Regression models and life tables. J R Stat Soc 34:187–196 Cox DR (1972) Regression models and life tables. J R Stat Soc 34:187–196
16.
go back to reference Weinberg J, Adler AJ (1989) Spurious hyperphosphatemia in patients with dysglobulinemia. Miner Electrolyte Metab 15:185–186PubMed Weinberg J, Adler AJ (1989) Spurious hyperphosphatemia in patients with dysglobulinemia. Miner Electrolyte Metab 15:185–186PubMed
17.
go back to reference McCloskey EV, Galloway J, Morgan MA, Kanis JA (1989) Pseudohyperphosphatemia in multiple myeloma. BMJ 299:1381–1382PubMed McCloskey EV, Galloway J, Morgan MA, Kanis JA (1989) Pseudohyperphosphatemia in multiple myeloma. BMJ 299:1381–1382PubMed
18.
go back to reference Barutcuoglu B, Parildar Z, Mutaf I, Habif S, Bayindir O (2003) Spuriously elevated inorganic phosphate level in a multiple myeloma patient. Clin Lab Haematol 25:271–274PubMedCrossRef Barutcuoglu B, Parildar Z, Mutaf I, Habif S, Bayindir O (2003) Spuriously elevated inorganic phosphate level in a multiple myeloma patient. Clin Lab Haematol 25:271–274PubMedCrossRef
19.
go back to reference Loghman-Adham M, Walton D, Iverius PH, Deiss A, Knight JA, Cheung AK (1997) Spurious hypophosphatemia in a patient with multiple myeloma. Am J Kidney Dis 30:571–575PubMedCrossRef Loghman-Adham M, Walton D, Iverius PH, Deiss A, Knight JA, Cheung AK (1997) Spurious hypophosphatemia in a patient with multiple myeloma. Am J Kidney Dis 30:571–575PubMedCrossRef
20.
go back to reference Caras JA (1997) Spurious hypophosphatemia associated with multiple myeloma. Endocr Pract 3:135–136PubMed Caras JA (1997) Spurious hypophosphatemia associated with multiple myeloma. Endocr Pract 3:135–136PubMed
21.
go back to reference Dash T, Parker MG, Lafayettw RA (1997) Profound hypophosphatemia and isolated hyperphosphaturia in two case of multiple myeloma. Am J Kidney Dis 29:445–448PubMedCrossRef Dash T, Parker MG, Lafayettw RA (1997) Profound hypophosphatemia and isolated hyperphosphaturia in two case of multiple myeloma. Am J Kidney Dis 29:445–448PubMedCrossRef
22.
go back to reference Weisbord SD, Chaudhuri A, Blauth K, DeRubertis FR (2003) Monoclonal gammopathy and spurious hypophosphatemia. Am J Med Sci 325:98–100PubMedCrossRef Weisbord SD, Chaudhuri A, Blauth K, DeRubertis FR (2003) Monoclonal gammopathy and spurious hypophosphatemia. Am J Med Sci 325:98–100PubMedCrossRef
23.
24.
go back to reference Smithline N, Kassirer JP, Cohen JJ (1976) Light-chain nephropathy: renal tubular dysfunction associated with light-chain proteinuria. N Engl J Med 294:71–74PubMed Smithline N, Kassirer JP, Cohen JJ (1976) Light-chain nephropathy: renal tubular dysfunction associated with light-chain proteinuria. N Engl J Med 294:71–74PubMed
25.
go back to reference Alexanian R, Balgerzak S, Bonnet JD, Gehan EA, Haut A, Hewlett JS, Monto RW (1975) Prognostic factors in multiple myeloma. Cancer 36:1192–1201PubMedCrossRef Alexanian R, Balgerzak S, Bonnet JD, Gehan EA, Haut A, Hewlett JS, Monto RW (1975) Prognostic factors in multiple myeloma. Cancer 36:1192–1201PubMedCrossRef
26.
go back to reference Merlini G, Waldenström JG, Jayakar SD (1980) A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood 55:1011–1019PubMed Merlini G, Waldenström JG, Jayakar SD (1980) A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood 55:1011–1019PubMed
27.
go back to reference Medical Research Council (1973) Report on the first myelomatosis trial. Part 1. Analysis of presenting features of prognostic importance. Br J Haematol 24:123–139CrossRef Medical Research Council (1973) Report on the first myelomatosis trial. Part 1. Analysis of presenting features of prognostic importance. Br J Haematol 24:123–139CrossRef
28.
go back to reference Bladé J, Rozman C, Cervantes F, Reverter J-C, Montserat E (1989) A new prognostic system for multiple myeloma based on easily available parameters. Br J Haematol 172:507–511CrossRef Bladé J, Rozman C, Cervantes F, Reverter J-C, Montserat E (1989) A new prognostic system for multiple myeloma based on easily available parameters. Br J Haematol 172:507–511CrossRef
29.
go back to reference San Miguel JF, Sànchez J, Gonzalez M (1989) Prognostic factors and classification in multiple myeloma. Br J Haematol 59:113–118 San Miguel JF, Sànchez J, Gonzalez M (1989) Prognostic factors and classification in multiple myeloma. Br J Haematol 59:113–118
30.
go back to reference Cavo M, Galieni P, Zuffa E, Baccarani M, Gobbi M, Tura S (1989) Prognostic variables and clinical staging in multiple myeloma. Blood 74:1774–1780PubMed Cavo M, Galieni P, Zuffa E, Baccarani M, Gobbi M, Tura S (1989) Prognostic variables and clinical staging in multiple myeloma. Blood 74:1774–1780PubMed
31.
go back to reference Murakami H, Kawada T, Saitoh T, Uchiumi H, Moridaira K, Matsushima T, Tsukamoto N, Tamura J, Morita K, Sawamura M, Karasawa M, Miyawaki S, Shinonome S, Shimano S, Sato S, Ogawara H, Tsuchiya J (1999) A staging system for multiple myeloma based on the morphology of myeloma cells. Eur J Haematol 62:63–67PubMedCrossRef Murakami H, Kawada T, Saitoh T, Uchiumi H, Moridaira K, Matsushima T, Tsukamoto N, Tamura J, Morita K, Sawamura M, Karasawa M, Miyawaki S, Shinonome S, Shimano S, Sato S, Ogawara H, Tsuchiya J (1999) A staging system for multiple myeloma based on the morphology of myeloma cells. Eur J Haematol 62:63–67PubMedCrossRef
32.
go back to reference Jacobson JL, Hussein MA, Barlogie B, Durie BGM, Crowley JJ (2003) A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 122:441–450PubMedCrossRef Jacobson JL, Hussein MA, Barlogie B, Durie BGM, Crowley JJ (2003) A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 122:441–450PubMedCrossRef
33.
go back to reference Durie BMG, Kyle RA, Belch A, Bensinger W, Bladé J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Poweles R, Singhal DS, Sirohi B, Sonnenveld P, Tricot G, Ness BV (2003) Myeloma management guidelines: a consensus report from the scientific advisors of the International Myeloma Foundation. Hematol J 4:379–398PubMedCrossRef Durie BMG, Kyle RA, Belch A, Bensinger W, Bladé J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Poweles R, Singhal DS, Sirohi B, Sonnenveld P, Tricot G, Ness BV (2003) Myeloma management guidelines: a consensus report from the scientific advisors of the International Myeloma Foundation. Hematol J 4:379–398PubMedCrossRef
Metadata
Title
Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma
Authors
Masanori Umeda
Shinya Okuda
Haruka Izumi
Daisuke Nagase
Yoshinori Fujimoto
Yasuyuki Sugasawa
Chiaki Arai
Kazuhiko Natori
Masako Katoh
Yasunobu Kuraishi
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 7/2006
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-006-0095-3

Other articles of this Issue 7/2006

Annals of Hematology 7/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.